Geron to Announce Second Quarter 2022 Financial Results on August 11, 2022

Rhea-AI Summary

Geron Corporation (NASDAQ: GERN) will release its Q2 2022 financial results on August 11, 2022, after the market closes. The details will be available on the company’s website. A conference call to discuss these results and upcoming milestones is scheduled for 4:30 p.m. ET on the same day. The call will be accessible via a live webcast on their site, with an archive available for 30 days. Geron is focused on developing its telomerase inhibitor, imetelstat, for hematologic malignancies and is conducting two Phase 3 trials.

Positive

• Geron is developing imetelstat, a first-in-class telomerase inhibitor.
• The company is conducting two Phase 3 clinical trials, IMerge and IMpactMF, indicating active progress in their drug development.

Negative

• None.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 11, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as key upcoming expected milestones at 4:30 p.m. ET the same day.

A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.

Participants may access the webcast by registering online using the following link, https://conferencingportals.com/event/SmvlMvWL. Participants that are unable to register online can access the conference call via telephone by dialing domestically +1 (888) 330-2434 or internationally +1 (240) 789-2725. The conference ID is 67335.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005001/en/

Aron Feingold

Investor and Media Relations

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

When will Geron Corporation release its Q2 2022 financial results?

Geron Corporation will release its Q2 2022 financial results on August 11, 2022.

What are the upcoming milestones for Geron Corporation?

Geron will discuss key upcoming milestones during the conference call on August 11, 2022.

How can I access the conference call for Geron's financial results?

The conference call can be accessed via a live webcast on Geron's website or by telephone at +1 (888) 330-2434.

What is Geron Corporation's focus in biopharmaceuticals?

Geron focuses on the development of a first-in-class telomerase inhibitor, imetelstat, for hematologic malignancies.